AKT1 and plasma cell myeloma: We previously showed that S14161 is a novel chromene-based inhibitor of pan-class I PI3Ks that inhibits the production of PI(3,4,5)P3 thus suppressing PI3K/AKT signaling transduction and displaying preclinical activity efficacy against multiple myeloma and leukemia without overt toxicity in vitro and in vivo, [23].